Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Cytori Therapeutics (CYTX)

Cytori Therapeutics (CYTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Cytori Therapeutics 3020 CALLAN ROAD SAN DIEGO CA 92121 USA

www.cytori.com P: 858-458-0900

Description:

Cytori Therapeutics, Inc. is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. The Company's preclinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders, and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem and regenerative cells, Cytori has developed its proprietary Celution System to isolate and concentrate a patient's own stem and regenerative cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients.

Key Statistics

Overview:

Market Capitalization, $K 4,602
Shares Outstanding, K 22,155
Annual Sales, $ 3,670 K
Annual Net Income, $ -12,630 K
Last Quarter Sales, $ 700 K
Last Quarter Net Income, $ -3,150 K
60-Month Beta 1.96
% of Insider Shareholders 0.80%
% of Institutional Shareholders 2.62%
Float, K 21,978
% Float 99.20%

Growth:

1-Year Return -67.55%
3-Year Return -99.04%
5-Year Return -99.93%
5-Year Revenue Growth -48.46%
5-Year Earnings Growth 97.52%
5-Year Dividend Growth 0.00%

Per-Share Information:

Latest Earnings Date 08/13/19
Earnings Per Share ttm -1.42
EPS Growth vs. Prev Qtr 10.00%
EPS Growth vs. Prev Year 74.29%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-10 on 05/24/18

CYTX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -272.70%
Return-on-Assets % -56.23%
Profit Margin % -344.14%
Debt/Equity 0.00
Price/Sales 1.33
Price/Cash Flow N/A
Price/Book 1.18
Book Value/Share 0.18
Interest Coverage -5.58
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar